Health Claims & Product Disclaimer

What KOVA Daily Strength is — and what it is not

KOVA Daily Strength is a daily food supplement in sachet form, providing creatine monohydrate (Creavitalis®/Creavitalis®), magnesium bisglycinate, vitamin D3 (cholecalciferol), and vitamin B12 (methylcobalamin). It is designed to be dissolved in water, coffee, a smoothie, or any cold or warm (not boiling) liquid and consumed once daily.

KOVA products are classified and sold as food supplements under EU Directive 2002/46/EC as implemented in Dutch law (Warenwetbesluit voedingssupplementen) and German law (NemV — Nahrungsergänzungsmittelverordnung). As a food supplement, KOVA Daily Strength is subject to EU food law, not pharmaceutical law. It does not require a prescription and does not undergo clinical approval by the EMA or any national medicines agency.

Our ingredients

KOVA Daily Strength contains four active ingredients. Each is present at a daily dose that falls within EFSA-assessed safe ranges and, where applicable, supports an authorised health claim under EU Regulation 1924/2006.

Creatine monohydrate — Creavitalis® / Creavitalis®

Creatine monohydrate is sourced from AlzChem Trostberg GmbH (Germany) under either the Creavitalis® or Creavitalis® quality specification, depending on batch. Both specifications are produced at the same GMP-certified facility in Trostberg, Germany, to an identical purity standard (≥99.9% pure creatine monohydrate). Creavitalis® and Creavitalis® are registered trademarks of AlzChem Trostberg GmbH; all rights in those marks remain with AlzChem.

Creatine monohydrate is one of the most extensively studied sports nutrition ingredients in the scientific literature. AlzChem’s production process results in a product free from creatinine, dicyandiamide (DCD), dihydrotriazine (DHT), and other synthesis-related impurities, and is independently tested for heavy metals, microbiological safety, and banned substance contamination.

Magnesium bisglycinate

Magnesium bisglycinate is a chelated form of magnesium bound to two glycine molecules. This form is selected for its superior gastrointestinal tolerability compared to inorganic magnesium salts (such as magnesium oxide or magnesium carbonate) and for its absorption profile. Each daily sachet provides 300 mg elemental magnesium, representing 80% of the EU Nutrient Reference Value (NRV) for magnesium (375 mg).

Vitamin D3 (cholecalciferol)

Each daily sachet provides 1000 IU (25 µg) of vitamin D3 as cholecalciferol. This dose is above the EU Nutrient Reference Value for vitamin D (5 µg / 200 IU) and above the German Bundesinstitut für Risikobewertung (BfR) daily recommendation of 800 IU (20 µg) for food supplements. The dose of 1000 IU is, however, well within the EFSA-established Tolerable Upper Intake Level (UL) of 4000 IU (100 µg) per day for adults and is widely used in the supplement literature as an effective daily maintenance dose. See Section 7 for the full BfR disclosure.

Vitamin B12 (methylcobalamin)

Each daily sachet provides 2.5 µg of vitamin B12 as methylcobalamin, representing 100% of the EU Nutrient Reference Value (NRV) for vitamin B12 (2.5 µg). Methylcobalamin is the bioactive, coenzyme form of B12, which does not require hepatic conversion before use by the body.

Authorised health claims — full register

Every health claim made by KOVA on its website, packaging, and marketing materials is drawn from the European Commission’s register of authorised health claims under EU Regulation 1924/2006. We do not make any claim that is not listed in this register. The table below documents every claim we use, the ingredient substantiating it, and its EU authorisation reference.

What we can and cannot claim

EU Regulation 1924/2006 draws a strict line between permitted nutrition and health claims and prohibited disease-risk reduction or treatment claims. The following table documents this boundary as it applies to KOVA.

Where KOVA’s website, email, social media, or any other marketing material refers to the science of creatine in perimenopause, cognition, bone density, or female physiology, this content is presented as educational information about the state of peer-reviewed research — not as a health claim made by KOVA about its product. All such content is clearly distinguished from our authorised health claims and is sourced from published, peer-reviewed literature.

Safe use — dosage, duration & precautions

5.1  Recommended daily use

Dissolve one sachet (one daily dose) in 250–300 ml of cold water, coffee, tea, a smoothie, or any other beverage. Stir or shake until fully dissolved. Consume once per day, preferably at the same time each day to build a consistent daily habit. Do not exceed one sachet per day unless advised by a healthcare professional.

5.2  Creatine and water intake

Creatine draws water into muscle cells as part of its mechanism of action. We recommend increasing your daily water intake by approximately 250–500 ml while taking KOVA Daily Strength, particularly during periods of regular exercise. This is not a safety concern — it is a practical recommendation to support the product’s efficacy and to avoid any sensation of mild bloating, which some users experience in the first 1–2 weeks of use.

5.3  Who should consult a doctor before use

• Pregnant or breastfeeding women — the safety of creatine supplementation during pregnancy and lactation has not been sufficiently studied in humans. We recommend consulting your GP or midwife before use.
• Persons with renal impairment or a history of kidney disease — creatine is metabolised and excreted via the kidneys. If you have been diagnosed with any degree of renal impairment or have a family history of kidney disease, consult your doctor before use.
• Persons taking prescription medication — if you are taking any prescription medication, particularly diuretics, nephrotoxic drugs, or any medication affecting renal function, consult your prescribing doctor before use.
• Persons with diabetes — creatine may affect blood glucose regulation in some individuals. If you have type 1 or type 2 diabetes, consult your doctor before use.
• Persons with a history of liver disease — while no evidence of hepatotoxicity from creatine supplementation at normal doses exists in healthy adults, consult your doctor if you have a diagnosed liver condition.

5.4  Not for children

KOVA Daily Strength is formulated for adults aged 18 and over. Keep out of reach of children. The safety of creatine supplementation in children and adolescents has not been evaluated by EFSA and we do not recommend use in persons under 18.

5.5  Adverse effects and interactions

Creatine monohydrate at the doses used in KOVA Daily Strength (5 g/day) is considered safe for healthy adults based on extensive peer-reviewed literature and the EFSA safety assessment. The most commonly reported minor side effects in a small proportion of users are mild gastrointestinal discomfort (nausea, stomach cramping, or loose stools) during the first 1–2 weeks of use. These effects typically resolve without intervention as the body adjusts.

If you experience any serious or persistent adverse effect that you believe may be associated with KOVA Daily Strength, discontinue use and consult a healthcare professional. Please also report the adverse effect to us at hello@takekova.com and, in the Netherlands, to the NVWA via nvwa.nl; in Germany, to the BVL via bvl.bund.de.

Allergens & product composition

6.1  Allergen declaration

KOVA Daily Strength does not contain any of the 14 major allergens listed in Annex II of EU Regulation 1169/2011 (as implemented in Dutch and German food labelling law) as intentional ingredients. The product is:

6.2  Full ingredient list

Each KOVA Daily Strength sachet contains: Creatine monohydrate (Creavitalis®/Creavitalis®), magnesium bisglycinate, maltodextrin (carrier), silicon dioxide (anti-caking agent), vitamin D3 (cholecalciferol — microencapsulated), vitamin B12 (methylcobalamin).

The full nutritional declaration and ingredient list is printed on every product sleeve and individual sachet in compliance with EU Regulation 1169/2011. The label on your product is the definitive ingredient reference for your specific batch. In the event of any discrepancy between the website and the physical label, the physical label takes precedence.

6.3  Heavy metals and contaminants

Every batch of Creavitalis®/Creavitalis® creatine monohydrate is tested by AlzChem Trostberg GmbH for heavy metal content (lead, arsenic, mercury, cadmium) and synthesis-related impurities (creatinine, DCD, DHT) in accordance with the limits set by EU Regulation 2023/915 and AlzChem’s own stricter internal specifications. A Certificate of Analysis (CoA) is available for every batch. Customers, healthcare professionals, or regulatory bodies may request the CoA for a specific batch by contacting hello@takekova.com with their order number and the batch number printed on the sleeve.

Vitamin D3 dosage — BfR disclosure

Why we chose 1000 IU

The BfR recommendation of 800 IU is a conservative population-level guideline designed to minimise the risk of excessive intake across all adult subgroups, including elderly individuals who may have reduced renal conversion of vitamin D. It is not an upper safety limit.

The EFSA Tolerable Upper Intake Level (UL) for vitamin D in adults is 4000 IU (100 µg) per day — four times the dose in KOVA Daily Strength. The UL represents the highest daily intake that is unlikely to cause adverse health effects in the general population over long-term use.

The 1000 IU dose is the most commonly used daily maintenance dose in peer-reviewed supplementation research on adult populations and is used as the reference dose in multiple European vitamin D status studies. Women in the 28–45 age range — KOVA’s primary demographic — have among the highest rates of vitamin D insufficiency in Northern Europe, particularly during autumn and winter months.

KOVA Daily Strength is intended to be the user’s only vitamin D supplement. If you are also taking a separate vitamin D supplement or a multivitamin containing vitamin D, ensure your total daily vitamin D intake from all sources does not exceed 4000 IU (the EFSA UL). If you are uncertain about your total intake, consult a healthcare professional.

The science behind our claims

KOVA’s marketing references peer-reviewed scientific literature to provide educational context for our ingredient choices. This section documents the basis for the scientific claims that appear on our website and in our communications. These are educational statements about the research landscape — they are not KOVA health claims.

Creatine monohydrate

The body of peer-reviewed research on creatine monohydrate comprises over 500 published studies. The following specific research areas are referenced in KOVA’s communications:

• Physical performance: Smith-Ryan et al. (2021) — Effects of creatine supplementation on exercise performance and fat-free mass in female athletes. Journal of Athletic Training. Demonstrated significant improvements in peak power and lean mass in resistance-trained women supplementing with 5 g creatine monohydrate daily.
• Cognitive function: Rae et al. (2003) — Oral creatine monohydrate supplementation improves brain performance. Proceedings of the Royal Society B: Biological Sciences. Double-blind, placebo-controlled trial showing significant improvement in working memory and intelligence tasks.
• Perimenopause and bone health: Chilibeck et al. (2015) — Effects of creatine and resistance training on bone health in postmenopausal women. Medicine & Science in Sports & Exercise. 52-week RCT showing that creatine supplementation combined with resistance training produced greater improvements in bone mineral content versus resistance training alone.
• Sleep and fatigue: Doherty et al. (2023) — Creatine supplementation reduced sleep deprivation–induced performance decrements and may mitigate the cognitive and physical effects of sleep disruption. Scientific Reports.
• General safety: Kreider et al. (2017) — International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. Comprehensive review concluding that creatine monohydrate is the most effective ergogenic nutritional supplement currently available and is safe for use in healthy adults.

Magnesium bisglycinate

• Bioavailability: Schuette et al. (1994) — Bioavailability of magnesium diglycinate vs. magnesium oxide in patients with ileal resection. Journal of Parenteral and Enteral Nutrition. Demonstrated superior absorption of chelated magnesium versus inorganic forms in compromised gut environments.
• Sleep quality: Abbasi et al. (2012) — The effect of magnesium supplementation on primary insomnia in elderly: a double-blind, placebo-controlled clinical trial. Journal of Research in Medical Sciences.

Vitamin D3 in women

• Prevalence of deficiency: Cashman et al. (2016) — Vitamin D deficiency in Europe: pandemic? The American Journal of Clinical Nutrition. Found that approximately 13% of EU adults have serum 25(OH)D below 30 nmol/L and 40% below 50 nmol/L year-round.
• Immune function and muscle: EFSA NDA Panel on Dietary Reference Values (2016) — the scientific basis for the EU authorised health claims for vitamin D relating to immune function and muscle function.

Full citations and links to source publications are available on our Science page at takekova.com/science. If you are a healthcare professional seeking specific research documentation, contact hello@takekova.com.

Reporting adverse effects

As a food business operator under EU Regulation 178/2002, we are legally required to investigate reports of adverse effects associated with our products and, where a safety risk to public health is confirmed, to notify the competent authorities.

If you believe you have experienced an adverse effect from KOVA Daily Strength, please:

• Discontinue use of the product.
• Seek medical attention if the effect is serious, persistent, or involves any symptom you are concerned about.
• Contact us at hello@takekova.com with: your order number, the batch number (printed on the sleeve and sachet), a description of the adverse effect, when it began, and whether you are taking any other medications or supplements.
• Retain the product and its packaging — do not dispose of them before contacting us.

You can also report adverse effects directly to the competent authority in your country:

We commit to acknowledging all adverse effect reports within 1 business day and to investigating and responding within 10 business days. Where a food safety risk is confirmed, we will notify the NVWA and/or BVL within the statutory timeframe and cooperate fully with any product recall or market withdrawal procedure.

Regulatory framework

The following legislation governs KOVA Daily Strength as a food supplement sold in the Netherlands and Germany:

Contact & questions

For any question about our ingredients, health claims, safety documentation, or regulatory compliance:

Food supplements are not substitutes for a varied, balanced diet and a healthy lifestyle. The information on this page is provided for transparency and regulatory compliance purposes. It does not constitute medical advice. If you have questions about whether KOVA Daily Strength is appropriate for your individual health circumstances, consult a qualified healthcare professional.